Latest Headlines

  1. Ibex Launches Galen Breast HER2, Supporting Improved Biomarker Scoring In Breast Cancer Patients 9/7/2023

    Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the launch of Galen™ Breast HER2, an AI-powered solution that aids pathologists in setting a higher standard for accurate and reproducible HER2 (human epidermal growth factor receptor 2) scoring in breast cancer patients.

  2. Circular Genomics Announces Partnership On Alzheimer’s Disease Biomarker Research 9/6/2023

    Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry, has announced a partnership with leading Alzheimer’s genomics expert Dr. Carlos Cruchaga to explore the role of circRNAs as blood biomarkers for early diagnosis and treatment of Alzheimer’s Disease. The work will expand upon the company’s ongoing primary depression research program.

  3. Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility Of EsoGuard® Esophageal Precancer Detection In Fire Fighters 9/6/2023

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced it has released positive data from a retrospective analysis demonstrating real-world clinical utility of EsoGuard® Esophageal DNA testing for the detection of esophageal precancer in a large cohort of fire fighters.

  4. SeptiCyte® RAPID Receives ICD-10-PCS Code From The U.S. Centers For Medicare & Medicaid Services (CMS) 9/6/2023

    Immunexpress, Pty Ltd., a molecular diagnostics company focused on improving outcomes for suspected sepsis patients, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted an International Classification of diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) code for Immunexpress' host response molecular test for sepsis, SeptiCyte® RAPID.

  5. Vitestro Starts Largest-Scale Clinical Trial Globally For Its Autonomous Blood Drawing Device, With Enrolment Of First Patients In A.D.O.P.T. 9/6/2023

    Vitestro, expert in medical robotics, has launched the A.D.O.P.T. Trial for its autonomous blood drawing device (image). With an anticipated sample size of over 10,000 patients, this is the most significant study globally to date of autonomous blood collection. Vitestro expects to obtain CE marking by the end of 2024.

  6. LabGenomics USA LLC Acquires QDx Pathology In A Strategic Move To Expand Its Diagnostic Lab Services And IVD Diagnostic Products Business Into The US Market 9/5/2023

    LabGenomics USA, a subsidiary of LabGenomics Co., Ltd., announced its acquisition of QDx Pathology, a leader in molecular and diagnostic pathology.

  7. Yourgene Health Launches Magbench Automated DNA Extraction Instrument And Kit For NIPT Workflows 9/5/2023

    Yourgene Health plc, a leading international molecular diagnostics group, today launched the Yourgene MagBench Automated DNA Extraction Instrument and Kit.

  8. Mainz Biomed Announces Strategic Partnership With Ärztliches Labor Dr. Buhlmann, Expanding Footprint In German Market 9/5/2023

    Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership with Ärztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market.

  9. Aspira Women’s Health Signs Exclusive Sample Procurement Agreement With The University Of Oxford 8/31/2023

    Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement with The University of Oxford for the procurement of serum samples to be used to verify and validate the Company’s endometriosis blood test algorithms.

  10. LivaNova Unveils Essenz In-Line Blood Monitor With U.S. FDA 510(k) Clearance And CE Mark 8/30/2023

    LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Mark for its Essenz In-Line Blood Monitor (ILBM), which provides accurate and continuous measurement of essential blood parameters to perfusionists throughout cardiopulmonary bypass (CPB) procedures.